Clinical Trial News
Early Antithymocyte Globulin Therapy Enhances Survival in Steroid-Resistant Acute GVHD Patients
A study reviewing the treatment of 79 hematopoetic stem cell transplant patients with steroid-resistant acute GVHD using equine antithymocyte globulin (ATG) showed a 32% survival rate at one year. The therapy was particularly effective in patients with skin GVHD and early signs of steroid resistance.
ASCO 2024: Lenvatinib plus Pembrolizumab Shows Superiority Over Sunitinib in Advanced Renal Cell Carcinoma
At the 2024 ASCO Annual Meeting, Dr. Viktor Grünwald presented findings from the CLEAR trial, highlighting the efficacy of lenvatinib plus pembrolizumab over sunitinib in treating advanced clear cell renal cell carcinoma. The combination therapy demonstrated significant improvements in overall survival, prolonged time to tumor progression across various organs, and a lower median tumor burden at disease progression.
Regional Chemotherapy for Liver Metastases of Colorectal Cancer Shows Varied Perfusion Patterns
A study involving 82 patients with liver metastases from colorectal cancer treated with continuous chemotherapy via hepatic artery infusion pumps revealed varied liver perfusion patterns. While 70% of patients showed homogeneous liver perfusion, 24% had distinct inhomogeneities, and 6% exhibited selective perfusion of one hepatic lobe, impacting the response to therapy.
Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver
A study involving 93 patients with colorectal cancer metastatic to the liver treated with hepatic arterial infusion of 5-fluorodeoxyuridine (FUDR) showed significant tumor size reduction and prolonged survival, especially in patients without extrahepatic metastases.
D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial
• A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
• The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
• Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.